Table 4.

Measured GFR thresholds and specificity for metabolic complicationa diagnosis with 90% sensitivity

ParameterHyperparathyroidismAnemiaAcidosisHyperkalemiaHyperphosphatemia
GFR (95% CI)Sp (%)GFR (95% CI)Sp (%)GFR (95% CI)Sp (%)GFR (95% CI)Sp (%)GFR (95% CI)Sp (%)
mGFR49.5 (49.4 to 49.6)3044.2 (44.1 to 44.3)3539.8 (39.7 to 39.9)4039.1 (39.0 to 39.1)4536.9 (36.8 to 37.0)45
eGFRcl46.5 (46.3 to 46.6)4251.7 (51.6 to 51.8)2345.4 (45.3 to 45.5)3641.4 (41.3 to 41.4)4438.0 (37.9 to 38.1)49
eGFRms46.8 (46.7 to 46.9)4246.5 (46.3 to 46.6)2742.4 (42.3 to 42.5)3639.1 (39.0 to 39.2)4336.2 (36.1 to 36.3)47
  • a Hyperparathyroidism was defined as a PTH >60 pg/ml or active vitamin D treatment; anemia was defined as Hb <110 g/L according to K/DOQI-based criteria or ESA treatment; acidosis was defined as a tCO2 <22 mmol/L or bicarbonate treatment; hyperkalemia was defined as a plasma potassium concentration >5 mmol/L or ion exchange resin treatment; hyperphosphatemia was defined as a plasma phosphate concentration >4.3 mg/dl (>1.38 mmol/L) or phosphate binder treatment.

    mGFR, measured glomerular filtration rate; eGFRcl, estimated glomerular filtration rate, using the MDRD Study equation with serum creatinine values calibrated by the Cleveland Clinic Laboratory; eGFRms, eGFR using the MDRD equation with serum creatinine values standardized to mass spectrometry.